5,374 Shares in Hologic, Inc. $HOLX Acquired by Petrus Trust Company LTA

Key Points

• Petrus Trust Company LTA invested approximately $332,000 in Hologic, Inc., acquiring 5,374 shares of the medical equipment provider in the first quarter.
• Analysts have issued new ratings and price targets for Hologic, with Citigroup upgrading the stock from "neutral" to "buy" and setting a target price of $80.00.
• Hologic reported quarterly earnings with $1.08 earnings per share, surpassing analysts' expectations, and has set its fiscal year 2025 guidance at 4.230-4.260 EPS.

Petrus Trust Company LTA acquired a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,374 shares of the medical equipment provider's stock, valued at approximately $332,000.

Other hedge funds have also recently modified their holdings of the company. Zions Bancorporation National Association UT purchased a new stake in shares of Hologic in the first quarter valued at about $34,000. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Hologic in the first quarter valued at about $42,000. Raiffeisen Bank International AG purchased a new stake in shares of Hologic in the fourth quarter valued at about $49,000. Allworth Financial LP grew its holdings in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the period. Finally, Larson Financial Group LLC boosted its stake in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after buying an additional 722 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Down 2.9%

Shares of NASDAQ HOLX traded down $1.93 during midday trading on Friday, hitting $64.45. The company's stock had a trading volume of 1,005,460 shares, compared to its average volume of 1,330,759. The business's fifty day simple moving average is $66.43 and its two-hundred day simple moving average is $62.64. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The firm has a market capitalization of $14.33 billion, a price-to-earnings ratio of 26.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the firm posted $1.06 earnings per share. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

HOLX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Argus raised shares of Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, August 18th. Morgan Stanley increased their target price on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Evercore ISI increased their target price on shares of Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Finally, Wall Street Zen raised shares of Hologic from a "hold" rating to a "buy" rating in a research note on Sunday, September 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, Hologic currently has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.